Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. - Wikidata - awgldk - TriplyDB

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

http://www.wikidata.org/entity/Q34536450

about

Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex Rapamycin and rapalogs for tuberous sclerosis complex Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models Management of lymphangioleiomyomatosis Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin Targeted topical and combination laser surgery for the treatment of angiofibromas.Lymphatic vascular morphogenesis in development, physiology, and disease Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex Cystic lung disease.mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD.Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases

P2860

Q24194140-7153B1B6-3DD7-45B9-B921-8D71111907B4 Q26471128-F95DD6B2-9F7F-42DF-949C-84BEB17E2CD3 Q27687650-1CF4C1B3-5F4B-4EE4-A4A0-27B64778002F Q28084725-55C86AA2-6C7C-45F4-A422-7DCE679979E2 Q30411083-B46E3577-A579-4433-9EDF-1563512291F3 Q33403043-EE0193DD-6E8D-416D-B68B-4D7F8724D624 Q35020019-F3CD5B54-B7BA-4385-9F22-7A95BEDF73FE Q35196040-E299FE5E-E5EA-459A-B697-F2DC6F829061 Q36462100-6F8233EC-7348-4AF1-AD78-94B8DDF55830 Q36636671-3CD7E516-9C65-459E-88B4-5FB398930548 Q37047634-C9197290-D64F-4407-98C1-16A620798429 Q37649083-54F41FD6-EAAB-4269-B2DC-51418EBD44ED Q38111303-2F10ACD3-CD44-42DF-ABBD-B6FE91F0ED32 Q38723770-0E9D6E45-97EF-4A6E-8F9A-3F8BB4D56099 Q46662378-3FAA838D-8857-48AF-8EA5-A8CCF751C912 Q49843469-EDF48483-3A58-4D08-82CE-377F1224FB4E Q51136450-CDB14083-C81E-4289-80AE-A28A1C0A5E3D Q57300947-E3DFDF41-8AA4-4E01-86A8-0578B66C137E

P2860

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

http://www.wikidata.org/entity/Q34536450

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@ast

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@en

type

label

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@ast

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@en

prefLabel

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@ast

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@en

P1433

Q34536450-21DA69CF-ABC3-412D-B6DB-C2828B1841EA

P1476

Q34536450-02BBE363-DBB0-4327-B319-3CF749A9E7F0

P2093

Q34536450-13CE0EED-BE0F-4635-B6AE-9F503499788E

Q34536450-181B9345-AA2A-4B5D-9A51-403FD7C4C4AE

Q34536450-1B889687-A245-4A7D-898F-0FD03766CF5B

Q34536450-377AE880-4E9A-4B63-A49D-016E187E39AC

Q34536450-95F6B021-2A76-4064-98F9-4EB701CDBB8C

Q34536450-9AA30C39-5370-494F-80E6-9E013319FE1A

Q34536450-ADA79F36-14B2-4EF9-B685-F1823430CA5F

Q34536450-F337F02D-066D-482D-80EB-407BBED6F2FD

Q34536450-F5F1BC14-CA5D-4184-845C-4F352A37272C

P2860

Q34536450-00283A49-36C7-4BEA-81D5-5EC59649FA7D

Q34536450-02DE124B-A51D-451A-BF19-DB43152DAC9D

Q34536450-0401DCCE-9033-4547-A9AF-79D763EF845C

Q34536450-053C3A52-BB1C-4288-9F63-48159DF7A608

Q34536450-055E4903-3C8B-4D1F-B6F5-FDA7AB533755

Q34536450-09215EBD-7ABC-4491-B4A7-DD1C7AF75CC0

Q34536450-0B0C9AB7-3C96-4D34-8D81-106A2CF1F9D6

Q34536450-0BE87357-CB1A-456C-9F79-0AC1DF04CBA1

Q34536450-0E9C2340-2A92-4091-9C3F-7ECB5ED9CA1B

Q34536450-1180E790-2C44-4840-890F-E0EBE8C07AF3

P304

Q34536450-773BA7B6-54DD-44B0-9BCD-A08ADAFA444E

P31

Q34536450-91D3917E-C90F-4A45-9C74-BB018474E9C6

P356

Q34536450-D287F7D3-9AE2-4F61-AC73-57E63F5522B5

P478

Q34536450-904CFD99-1652-4ECC-8E94-383386C2612B

P577

Q34536450-9A802A4C-7DFE-4863-891F-37D3B6D4AF45

P5875

Q34536450-CD165D9C-39ED-41D1-81B5-FB01EF588771

P698

Q34536450-EF36BE15-764F-4307-B043-58C47FEFF96F

P932

Q34536450-0C7641AF-91CF-4CAC-8684-C6E0DE6D8FB7

P356

J.RMED.2010.03.017

P1433

Respiratory Medicine

P1476

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

@en

P2093

Angelo Taveira-Dasilva

http://www.w3.org/2001/XMLSchema#string

Connie G Glasgow

http://www.w3.org/2001/XMLSchema#string

Gustavo Pacheco-Rodriguez

http://www.w3.org/2001/XMLSchema#string

Joel Moss

http://www.w3.org/2001/XMLSchema#string

Marsha Moses

http://www.w3.org/2001/XMLSchema#string

Souheil El-Chemaly

http://www.w3.org/2001/XMLSchema#string

Thomas Darling

http://www.w3.org/2001/XMLSchema#string

Wendy K Steagall

http://www.w3.org/2001/XMLSchema#string

Xiong Cai

http://www.w3.org/2001/XMLSchema#string

P2860

Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles

Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination

Involvement of chemokine receptors in breast cancer metastasis

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Cell cycle, CDKs and cancer: a changing paradigm

P304

S45-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.RMED.2010.03.017

http://www.w3.org/2001/XMLSchema#string

P478

104 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51444327

http://www.w3.org/2001/XMLSchema#string

P698

20630348

http://www.w3.org/2001/XMLSchema#string

P932

3030250

http://www.w3.org/2001/XMLSchema#string